Market revenue in 2023 | USD 70.0 million |
Market revenue in 2030 | USD 179.5 million |
Growth rate | 14.4% (CAGR from 2023 to 2030) |
Largest segment | Biorepository services |
Fastest growing segment | Biorepository Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biorepository Services, Archiving Solution Services |
Key market players worldwide | Azenta Inc, Thermo Fisher Scientific Inc, Precision for Medicine, Medpace Holdings Inc, Labcorp Drug Development, ATCC, Q2 Solutions, LabConnect, Charles River Laboratories International Inc |
Biorepository services was the largest segment with a revenue share of 66.29% in 2023. Horizon Databook has segmented the Australia clinical trial biorepository & archiving solutions market based on biorepository services, archiving solution services covering the revenue growth of each sub-segment from 2018 to 2030.
Stringent regulatory policies related to clinical trials in Australia may hinder market growth over the forecast period. In Australia, therapeutic goods used in clinical trials are classified under therapeutic goods legislation. Clinical trial sponsors should be aware about the requirements of export, import, manufacture, and supply of therapeutic goods in Australia.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account